MA42444A - Traitement du prurit - Google Patents

Traitement du prurit

Info

Publication number
MA42444A
MA42444A MA042444A MA42444A MA42444A MA 42444 A MA42444 A MA 42444A MA 042444 A MA042444 A MA 042444A MA 42444 A MA42444 A MA 42444A MA 42444 A MA42444 A MA 42444A
Authority
MA
Morocco
Prior art keywords
pruritus
treatment
Prior art date
Application number
MA042444A
Other languages
English (en)
Inventor
Matthew D Linnik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42444A publication Critical patent/MA42444A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042444A 2015-07-16 2016-07-07 Traitement du prurit MA42444A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562193335P 2015-07-16 2015-07-16

Publications (1)

Publication Number Publication Date
MA42444A true MA42444A (fr) 2018-05-23

Family

ID=56464322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042444A MA42444A (fr) 2015-07-16 2016-07-07 Traitement du prurit

Country Status (13)

Country Link
US (1) US20180201673A1 (fr)
EP (1) EP3322725A1 (fr)
JP (1) JP2018521047A (fr)
KR (1) KR20180017145A (fr)
CN (1) CN107849128A (fr)
AU (1) AU2016294332A1 (fr)
BR (1) BR112017025264A2 (fr)
CA (1) CA2988240A1 (fr)
EA (1) EA201792527A1 (fr)
IL (1) IL255498A (fr)
MA (1) MA42444A (fr)
MX (1) MX2018000694A (fr)
WO (1) WO2017011260A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672988A1 (fr) * 2017-08-23 2020-07-01 Eli Lilly and Company Traitement du psoriasis génital
JP6930778B2 (ja) * 2018-05-17 2021-09-01 江蘇▲筌▼信生物医薬有限公司Ｑｙｕｎｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
MA55033A (fr) * 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
CN118078988A (zh) * 2024-04-19 2024-05-28 正大天晴药业集团南京顺欣制药有限公司 包含靶向il-17a的抗体药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US7501247B2 (en) * 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
WO2007070750A1 (fr) 2005-12-13 2007-06-21 Eli Lilly And Company Anticorps anti-il-17
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
WO2012125680A1 (fr) * 2011-03-16 2012-09-20 Novartis Ag Méthodes de traitement de vascularite à l'aide d'un molécule de liaison à l'il-17
WO2014107737A2 (fr) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Administration locale d'inhibiteurs de l'il-17 en vue du traitement d'affections oculaires

Also Published As

Publication number Publication date
MX2018000694A (es) 2018-05-07
KR20180017145A (ko) 2018-02-20
US20180201673A1 (en) 2018-07-19
EP3322725A1 (fr) 2018-05-23
EA201792527A1 (ru) 2018-06-29
JP2018521047A (ja) 2018-08-02
IL255498A (en) 2018-01-31
CA2988240A1 (fr) 2017-01-19
CN107849128A (zh) 2018-03-27
WO2017011260A1 (fr) 2017-01-19
BR112017025264A2 (pt) 2018-08-07
AU2016294332A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
EP3359171C0 (fr) Utilisation d'akkermansia muciniphila pour traiter des états inflammatoires
MA43190A (fr) Traitement de la dyslipidémie mixte
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3125875T3 (da) Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
IL253118A0 (en) Methods for treating inflammatory diseases
SG11201609652RA (en) Treatment of polybacterials infections
HK1252037A1 (zh) 治療炎性疾病的方法
DK3283210T3 (da) Fremgangsmåde
DK3307267T3 (da) Behandling af multipel sklerose
HK1258611A1 (zh) 腹水的治療
DK3453721T3 (da) Process of manufacture of annexin v
MA47408A (fr) Traitement du cancer
DK3132009T3 (da) Fremgangsmåde
MA42999A (fr) Polythérapie pour le traitement de malignités
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
MA42444A (fr) Traitement du prurit
FR3022129B1 (fr) Baignoire de puericulture
DK3200783T3 (da) Behandling af erytromelalgi
DK2965765T3 (da) Anvendelse af adelmidrol til behandling af epiteldysfunktioner
ES1137506Y (es) Helice reductora de perdidas
FR3024647B1 (fr) Transat de puericulture
HK1246679A1 (zh) 絲蟲病的治療